secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106243
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT Q2 net loss $54.7M; accelerates 4D-150 Phase 3 wet AMD data to H1 2027
---------------------------------------------------------------------------

- Cash $417M (down from $505M Dec 2024); funds into 2028; workforce cut ~25% saves ~$15M/yr.
- Net loss $54.7M vs $35.0M Q2 2024; R&D spend $48.0M (+50% YoY) on Phase 3 startup.
- 4FRONT-1 wet AMD Phase 3 topline data accelerated to H1 2027; 4FRONT-2 initiated ahead of schedule.
- DME SPECTRA 60-wk: Phase 3 dose 78% fewer injections vs on-label aflibercept; FDA/EMA align on single-study approval.
- RMAT designation for 4D-150 in DME; 4D-710 cystic fibrosis cohort enrollment complete, data Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/0000950170-25-106243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/fdmt-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer